Table 2 Total and stratified analysis of MTHFR rs1801131 A/C polymorphism and each urinary cancer variables
Variables | N | Case/Control | C-allele vs. A-allele | CA vs. AA | CC vs. CA + AA | CC + CA vs. AA |
|---|---|---|---|---|---|---|
OR(95%CI) Ph | OR(95%CI) Ph | OR(95%CI) Ph | OR(95%CI) Ph | |||
Total | 28 | 9110/12105 | 1.06(0.98–1.15)0.000 | 1.12(1.01–1.24)0.000 | 1.01(0.87–1.17)0.021 | 1.09(1.00–1.19)0.003 |
HWE | 25 | 8747/11657 | 1.03(0.96–1.11)0.001 | 1.11(1.00–1.24)0.000 | 0.93(0.84–1.02)0.432 | 1.06(0.98–1.16)0.006 |
Prostate cancer | ||||||
Total | 11 | 4419/6587 | 1.02(0.91–1.14)0.016 | 0.99(0.91–1.07)0.569 | 1.00(0.81–1.25)0.062 | 0.99(0.91–1.07)0.253 |
HWE | 9 | 4224/6311 | 0.96(0.91–1.02)0.656 | 0.99(0.91–1.07)0.423 | 0.90(0.79–1.04)0.918 | 0.97(0.90–1.05)0.461 |
Ethnicity | ||||||
Caucasian | 8 | 3545/5453 | 1.02(0.88–1.17)0.008 | 0.96(0.88–1.06)0.622 | 0.96(0.83–1.10)0.020 | 0.96(0.88–1.05)0.244 |
Asian | 2 | 435/656 | 1.02(0.81–1.27)0.250 | 0.97(0.75–1.27)0.392 | 1.23(0.61–2.48)0.546 | 0.99(0.77–1.29)0.300 |
Mixed | 1 | 439/478 | NA | NA | NA | NA |
Source of control | ||||||
HB | 6 | 958/1421 | 1.05(0.81–1.37)0.003 | 0.93(0.78–1.12)0.701 | 0.57(0.44–0.75)0.530 | 1.09(0.64–1.85)0.017 |
PB | 5 | 3461/5166 | 0.97(0.91–1.04)0.485 | 1.00(0.91–1.10)0.269 | 1.08(0.85–1.36)0.004 | 0.91(0.79–1.06)0.885 |
BPH | 3 | 389/428 | 1.22(0.70–2.13)0.004 | 0.95(0.68–1.31)0.411 | 1.22(0.44–3.40)0.310 | 1.12(0.84–1.50)0.116 |
Healthy | 8 | 4030/6159 | 0.97(0.91–1.03)0.454 | 0.99(0.91–1.08)0.454 | 0.91(0.79–1.05)0.863 | 0.98(0.90–1.06)0.39 |
Bladder cancer | ||||||
Total | 14 | 3553/3955 | 1.04(0.93–1.16)0.009 | 1.17(0.99–1.38)0.005 | 0.89(0.74–1.06)0.268 | 1.07(0.98–1.17)0.259 |
Ethnicity | ||||||
Caucasian | 7 | 2512/2912 | 1.01(0.90–1.14)0.085 | 1.17(0.92–1.48)0.001 | 0.90(0.66–1.23)0.033 | 1.09(0.93–1.29)0.069 |
Asian | 2 | 551/575 | 1.35(1.15–1.60)0.941 | 0.98(0.76–1.27)0.599 | 0.92(0.38–2.25)0.893 | 1.11(0.91–1.36)0.792 |
Mixed | 2 | 123/125 | 0.75(0.51–1.09)0.286 | 1.00(0.59–1.70)0.594 | 1.04(0.41–2.65)0.469 | 0.78(0.48–1.27)0.258 |
African | 3 | 317/343 | 0.91(0.72–1.14)0.627 | 1.63(1.17–2.25)0.498 | 0.88(0.44–1.75)0.702 | 1.20(0.90–1.59)0.787 |
Source of control | ||||||
HB | 5 | 813/1013 | 1.16(0.90–1.49)0.024 | 1.49(0.96–2.30)0.002 | 1.24(0.84–1.84)0.137 | 1.29(1.09–1.54)0.235 |
PB | 9 | 2740/2942 | 0.99(0.91–1.07)0.103 | 1.05(0.94–1.17)0.902 | 0.82(0.67–0.99)0.788 | 1.00(0.91–1.11)0.829 |
Renal cell carcinoma | ||||||
Total | 3 | 1138/1563 | 1.33(0.90–1.98)0.000 | 1.47(0.81–2.68)0.000 | 1.50(0.86–2.59)0.041 | 1.54(0.82–2.92)0.000 |
HWE | 2 | 970/1391 | 1.32(0.72–2.42)0.000 | 1.54(0.59–4.03)0.000 | 1.26(0.74–2.14)0.080 | 1.58(0.58–4.28)0.000 |